Meaverin

Mepivacaine, the active ingredient in Meaverin, is a local anesthetic presented as a sterile solution for epidural, intradermal and subcutaneous use. It provides reversible nerve block to facilitate temporary loss of sensation during minor surgical and diagnostic procedures. GNH USA supplies Meaverin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mepivacaine is a local anesthetic used to achieve temporary sensory blockade in specific procedural pathways. - Epidural anesthesia: provides analgesia for labor or surgical procedures requiring epidural block. - Intradermal anesthesia: enables numbing of skin for minor surgical or diagnostic procedures. - Subcutaneous anesthesia: facilitates pain‑free injection or minor surgery beneath the skin.

Mepivacaine may cause a range of adverse reactions, from mild to severe, depending on the site of administration and patient sensitivity.

Common Side Effects: - Transient burning or stinging sensation at the injection site. - Mild swelling or erythema around the administered area. - Tingling or temporary numbness extending beyond the target region.

Serious or Rare Side Effects: - Allergic reaction including anaphylaxis. - Cardiac arrhythmias such as ventricular tachycardia. - Central nervous system toxicity manifesting as seizures. - Methemoglobinemia leading to reduced oxygen delivery. - Persistent motor block or prolonged numbness.

When using Meaverin, clinicians should observe several safety measures to minimise risk. - Assess patient allergy: confirm no known hypersensitivity to amide‑type local anesthetics. - Use caution in cardiac disease: monitor heart rhythm during and after administration. - Avoid excessive dosage: adhere to recommended maximum dose per procedure. - Consider renal or hepatic impairment: adjust usage as clinically indicated. - Pregnancy and breastfeeding: use only if benefit outweighs potential risk. - Store at below 25°C: keep in original container, protect from light and moisture.

Mepivacaine can interact with other medications, necessitating careful review of a patient’s drug regimen.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase cardiotoxicity. - Beta‑blockers: can potentiate bradycardia. - Monoamine oxidase inhibitors: may enhance systemic toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may increase bleeding risk at injection site. - General anesthetics (e.g., propofol): additive central nervous system depression. - Other local anesthetics: cumulative toxicity if combined.